Company News - China Merchants Jinling (00978.HK) reported a total contract sales of approximately 32.308 billion yuan for 2025, representing a year-on-year decrease of 23.91% [2] - ZTE Corporation (00763.HK) plans to invest 117 million yuan to subscribe to shares of Jianxing Zhanlu Fund, which aims to support a broader range of innovative businesses and upstream and downstream industry chain enterprises [2] - Cloud Factory (02512.HK) announced that its subsidiary won a bid for the second phase of the artificial intelligence industry base project, with a contract value of 520 million yuan [2] - XPeng Motors-W (09868.HK) delivered 20,011 new vehicles in January [3] - La Jiao Network Entertainment (08172.HK) announced that its subsidiary, La Jiao Zhongbo, received authorization from Ant Group to become the "official service provider" for "Ant Treasure Box" [3] - Jun Dong Holdings (08277.HK) signed a timber harvesting and sales agreement with Jinda Forestry through its subsidiary Hebei Linmu [3] - Global Medical (02666.HK) plans to issue corporate bonds with a total principal amount not exceeding 1 billion yuan [3] - Junsheng Tai Pharmaceutical-B (02511.HK) appointed Dr. Filip Surmont as Chief Medical Officer to strengthen its layout in chronic kidney and metabolic diseases (CKM) [3] - Blue River Holdings (00498.HK) entered into a cooperation framework agreement with Energy Storage Investment Company [3] Financing and Buyback Activities - Junda Co., Ltd. (02865.HK) completed a placement of 18.682 million shares, raising approximately 398 million HKD [4] - Xiaomi Group-W (01810.HK) repurchased 6 million shares for a total of 209 million HKD, with repurchase prices ranging from 34.54 to 35.00 HKD [4] - Country Garden Services (06098.HK) repurchased 1.8 million shares for a total of 11.346 million HKD, with repurchase prices between 6.26 and 6.35 HKD [5] - Vitasoy International (00345.HK) repurchased 1.682 million shares for a total of 11.7363 million HKD, with repurchase prices between 6.89 and 7 HKD [6] - Aikang Medical (01789.HK) plans to use up to 150 million HKD for share buybacks [7]

Group 1 - The company announced the appointment of Dr. Filip Surmont as Chief Medical Officer [1] - Dr. Surmont will be responsible for the company's medical strategy, clinical development, and related medical affairs [1] - The appointment aims to support the development and value enhancement of the company's core pipeline in the cardiovascular, kidney, and metabolic diseases (CKM) sector [1]

Group 1 - The core point of the article is the appointment of Dr. Filip Surmont as Chief Medical Officer of Junsheng Tai Pharmaceutical-B (02511), who will oversee the company's medical strategy, clinical development, and related medical affairs [1] - The appointment aims to enhance the research and development progress and value of the company's core pipeline in the field of cardio-renal metabolic diseases (CKM) [1]

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) has appointed Dr. Filip Surmont as Chief Medical Officer to oversee the company's medical strategy, clinical development, and related medical affairs, aiming to enhance the research and value of its core pipeline in the cardiovascular, kidney, and metabolic (CKM) disease area [1] Group 1 - The appointment of Dr. Filip Surmont is expected to strengthen the company's focus on its medical strategy [1] - Dr. Surmont will be responsible for clinical development and related medical affairs [1] - The company aims to advance its core pipeline in the CKM disease sector [1]

Core Viewpoint - The company reported a significant reduction in losses for the first half of 2025, with a loss of RMB 113.9 million compared to RMB 210.9 million in the same period of 2024, indicating improved financial performance [1] Group 1: Financial Performance - The company recorded a loss of RMB 113.9 million in the first half of 2025, a substantial decrease from the loss of RMB 210.9 million in the first half of 2024 [1] Group 2: Product Pipeline and Innovation - The company is focusing on the potential of its core product HTD1801, which is being developed globally for treating chronic kidney and metabolic diseases, including Type 2 diabetes, metabolic-associated fatty liver disease, chronic kidney disease, obesity, primary sclerosing cholangitis, and severe hypertriglyceridemia [1] - HTD1801 is a novel molecular entity targeting the gut-liver system, acting as an oral anti-inflammatory and metabolic modulator through a dual mechanism of activating AMPK and inhibiting the NLRP3 inflammasome [2] - The company has developed a strong pipeline of innovative drug candidates, including HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting ten potential indications [1][2] Group 3: Market Opportunity and Demand - The treatment market for chronic kidney and metabolic diseases (CKM) is substantial, affecting nearly 90% of adults in the U.S. and 80% in China, with approximately 590 million diabetes patients globally, indicating a significant unmet need for innovative therapies [3] - HTD1801's dual mechanism shows exceptional therapeutic potential in addressing CKM-related diseases, with clinical studies confirming its multiple benefits in metabolism, kidney function, obesity, and cardiovascular complications [3] Group 4: Intellectual Property and Commercialization Strategy - The company maintains a robust intellectual property portfolio with over 100 patents and applications globally, providing effective market access barriers and supporting its commercialization goals [4] - As HTD1801 approaches commercialization in 2025, the company aims to capitalize on market opportunities and expand its market presence [4]